Anna Lladó

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Luca Gianni, Anna Lladó, Giulia Bianchi et al. · Journal of Clinical Oncology · 2010 · 269 citations

Medicine, Oncology, Pharmacology +17

Self-Sensing Enzyme-Powered Micromotors Equipped with pH-Responsive DNA Nanoswitches

Tania Patiño, Alessandro Porchetta, Anita Jannasch et al. · Nano Letters · 2019 · 175 citations

Engineering, Bioengineering, Biotechnology +16

Autophagy-induced senescence is regulated by p38α signaling

Konstantin Slobodnyuk, Nevenka Radic, Saška Ivanova et al. · Cell Death and Disease · 2019 · 82 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors

Elisa Rivas, Jenniffer Linares, Melissa Zwick et al. · Nature Communications · 2022 · 69 citations · Full text

Medicine, Immunology, Oncology +17

Protein Kinase Cδ and Calmodulin Regulate Epidermal Growth Factor Receptor Recycling from Early Endosomes through Arp2/3 Complex and Cortactin

Anna Lladó, Paul Timpson, Sandra Vilà de Muga et al. · Molecular Biology of the Cell · 2007 · 46 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17